Analyse av kostnader knyttet til dagens regulering av illegale rusmidler til eget bruk og håndhevingen av den eksisterende kontrollpolitikken

Report number: OE-rapport 2019-40
Title: Analyse av kostnader knyttet til dagens regulering av illegale rusmidler til eget bruk og håndhevingen av den eksisterende kontrollpolitikken
Client: Helse- og omsorgsdepartementet
Published: October 19
Link: PDF

See all publications

Newest articles

Court of Appeals: Excluding commercial providers from public procurement of nursing homes was unlawful

In a case between Oslo municipality and two commercial providers of nursing homes (Norlandia and Stendi), Borgarting Court of Appeals has decided that Oslo municipality’s exclusion of commercial providers from a public procurement of nursing home services was unlawful.

Study reveals potential for improving adherence to lipid lowering treatment

Our recently published study on adherence to lipid-lowering drugs was featured in a newspaper article in Dagens Medisin. Our study tracks all patients in Norway who initiated treatment with proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) from 2015 to 2023.

Alternative clinical endpoints: The path to better treatment?

On November 27, Oslo Economics and Bristol Myers Squibb are hosting a breakfast meeting on the healthcare system’s structure and its ability to prioritize in today’s rapidly evolving technological landscape.
Join us to hear presentations from a range of engaging speakers and participate in the discussion.

Analyse av kostnader knyttet til dagens regulering av illegale rusmidler til eget bruk og håndhevingen av den eksisterende kontrollpolitikken

Court of Appeals: Excluding commercial providers from public procurement of nursing homes was unlawful

Study reveals potential for improving adherence to lipid lowering treatment

Alternative clinical endpoints: The path to better treatment?

Bergen

Oslo

Berlin